Clarivate Sheds Life Sciences Unit in $600 Million Deal

The transaction, which is expected to close by the end of 2026, involves $500 million in cash at closing, $25 million in deferred payments, and a $75 million seller note. Clarivate plans to direct the proceeds toward debt reduction to strengthen its balance sheet and improve its overall financial flexibility.

CEO Matti Shem Tov described the divestiture as a cornerstone of the company’s four-pillared Value Creation Plan, aimed at optimizing the business model and accelerating innovation. By narrowing its focus, the firm intends to improve its revenue mix and lower capital intensity. Following the sale, the company will be classified as a subscription-first provider, leveraging deep customer relationships within its remaining segments to drive growth in the knowledge and innovation economy.